Gyre Therapeutics (GYRE) GC holds option for 47,530 shares
Rhea-AI Filing Summary
Gyre Therapeutics, Inc. executive Joshua Benjamin Bergmann, the company’s GC and Corporate Secretary, reported his initial ownership of a stock option in a Form 3 filing. The option gives him the right to buy 47,530 shares of common stock at an exercise price of $8.09 per share.
According to the filing, the option expires on February 27, 2036. One quarter of the option will vest on June 16, 2026, and the remaining three quarters will vest in equal monthly installments over the following three years, as long as he continues serving the company on each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bergmann Joshua Benjamin
Role
GC and Corporate Secretary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 47,530 shares (Direct)
Footnotes (1)
- F1. This option represents a right to purchase 47,530 shares of the Issuer's common stock, one quarter of which will vest on June 16, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying shares: 47,530 shares
Exercise price: $8.09 per share
Option expiration: February 27, 2036
+2 more
5 metrics
Underlying shares
47,530 shares
Common stock underlying reported stock option
Exercise price
$8.09 per share
Exercise price for stock option right to buy common stock
Option expiration
February 27, 2036
Expiration date of reported stock option
Initial vesting date
June 16, 2026
One quarter of option vests on this date
Remaining vesting period
Three years
Remaining three quarters vest monthly over following three years
Key Terms
Stock Option (Right to Buy), vest, exercise price, underlying security, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vest financial
"one quarter of which will vest on June 16, 2026"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: 8.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title: Common Stock"
Form 3 regulatory
"INSIDER FILING DATA (Form 3)"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did GYRE’s GC report in this Form 3 filing?
Joshua Benjamin Bergmann, GC and Corporate Secretary of Gyre Therapeutics (GYRE), reported an initial holding of a stock option. The option covers 47,530 shares of common stock, reflecting his equity-based compensation position with the company.
What is the exercise price of the reported GYRE stock option?
The reported stock option for Gyre Therapeutics (GYRE) has an exercise price of $8.09 per share. This means Bergmann can buy common shares at $8.09 once the option vests, if he chooses to exercise the option before it expires.
When does Bergmann’s GYRE stock option vest?
According to the filing, 25% of the option vests on June 16, 2026. The remaining 75% then vests in equal monthly installments over the next three years, subject to Bergmann’s continued service with Gyre Therapeutics on each vesting date.
When does the reported GYRE stock option expire?
The stock option reported by Gyre Therapeutics (GYRE) executive Joshua Benjamin Bergmann expires on February 27, 2036. He must exercise any vested portion of the option before that expiration date, or the right to purchase those shares will lapse.